Trinity Biotech

Trinity Biotech Pre-Tax Margin

The Pre-Tax Profit Margin of Trinity Biotech (TRIB) as of Oct 16, 2026 is -84.91 %. In the previous year, Pre-Tax Profit Margin was -49.92 % — a change of 70.08% (lower).

Pre-Tax Margin

-84.91 %

YoY

70.08%

Last updated:

Pre-Tax Profit Margin of Trinity Biotech is 2025 -84.91 % . Pre-Tax Profit Margin of Trinity Biotech was 2024 -49.92 % . It decreases by 70.08% lower compared to the previous year.

The Trinity Biotech Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
3.12 USD
Jan 1, 2019
0.91 USD
Jan 1, 2020
-6.50 USD
Jan 1, 2021
-2.37 USD
Jan 1, 2022
-70.02 USD
Jan 1, 2023
-64.98 USD
Jan 1, 2024
-49.92 USD
Jan 1, 2025
-84.91 USD
The Trinity Biotech Pre-Tax Margin history
YEARPre-Tax MarginYoY
-84.91 %+70.08%
-49.92 %-23.17%
-64.98 %-7.21%
-70.02 %+2,853.44%
-2.37 %-63.55%
-6.50 %-816.45%
0.91 %-70.90%
3.12 %+92.81%
1.62 %-68.97%
5.21 %-77.16%
22.83 %+32.54%
17.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Pre-Tax Profit Margin of Trinity Biotech is -84.91 % in 2025.

Pre-Tax Profit Margin of Trinity Biotech changed from -49.92 % to -84.91 %, representing a 70.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Trinity Biotech

All Key Metrics — Trinity Biotech